What is Thymosin Alpha-1?

Thymosin alpha-1 is a 28-amino-acid thymic peptide, also called thymalfasin, studied and used internationally as an immune modulator. [1][2][3]

Its best-known clinical settings include chronic viral hepatitis, immune dysfunction, vaccine-response adjunct research, and infection-related immune modulation. [1][2][3]

U.S. status is separate from international use: thymalfasin products may exist abroad, but thymosin alpha-1 is not FDA-approved as a U.S. drug product. [1][2][3]

What Thymosin Alpha-1 is investigated for

Thymosin Alpha-1 evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Immune system modulation

Injectable

68% Moderate

Immune modulation is the broadest thymosin alpha-1 claim, while condition-specific claims need separate evidence grades. [1][6][3]

Human evidence

Reviews describe thymosin alpha-1 as an immune-system modulator with clinical use in several infectious-disease contexts outside the U.S. approval framework. [1][6][3]

Animal / mechanistic evidence

Mechanistic literature supports T-cell and innate/adaptive immune modulation. [1][6][3]

Hepatitis B and C adjunct treatment

Injectable

66% Moderate

Viral hepatitis is specifically human-studied and is not the same as generic immune support. [5][7][8]

Human evidence

Chronic hepatitis B literature and meta-analysis support thymosin alpha-1 as an adjunct or historical therapy in viral hepatitis contexts. [5][7][8]

Animal / mechanistic evidence

The hepatitis rationale follows immune enhancement rather than direct antiviral substitution. [5][7][8]

Vaccine response and antiviral adjunct support

Injectable

58% Emerging

Vaccine and antiviral-adjunct support has limited human evidence, not general infection-prevention evidence. [6][2][3]

Human evidence

Reviews describe vaccine-response and antiviral-adjunct applications, but the evidence is less uniform than the hepatitis literature. [6][2][3]

Animal / mechanistic evidence

Immune-modulation mechanisms provide plausibility for vaccine and antiviral-adjunct research. [6][2][3]

Acute illness and post-viral immune support

Injectable

44% Preliminary

Acute and post-viral immune support remains preliminary and condition-specific. [3][2][6]

Human evidence

Broader viral-infection reviews discuss thymosin alpha-1 in acute and post-viral immune contexts, but U.S. approval-level evidence is not established. [3][2][6]

Animal / mechanistic evidence

Mechanistic immune effects support the rationale, while condition-specific outcomes vary. [3][2][6]

Evidence snapshot

Overall confidence

Moderate

68%

Thymosin alpha-1 has moderate support for immune modulation in indication-specific clinical literature, especially internationally. Wellness-style immune uses need narrower wording. [1][2][3]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

68%

Human evidence

Moderate

Clinical literature and reviews exist for immune and infection-related settings, especially outside the U.S. The evidence is meaningful but indication-specific. [1][2][3]

34%

Animal / preclinical

Limited

Mechanistic work supports T-cell, dendritic-cell, and innate immune modulation. [1][2][3]

68%

Mechanism support

Moderate

Thymosin alpha-1 is discussed around T-cell, dendritic-cell, interferon, and innate immune signaling. The mechanism fits immune-response coordination rather than direct antimicrobial action. [1][2][3]

Forms & administration

Thymosin Alpha-1 is tracked as an injectable immune-modulating peptide. Thymalfasin-style clinical use is separate from compounded or research-market products. [17][18][1]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable protocols usually use 1.5 mg per dose. [17][18][1]

Frequency

Common injectable schedules use 2-3 doses weekly. [17][18][1]

Timing Considerations

Morning timing is the common anchor; meal timing is less important than consistent weekly spacing. [17][18][1]

Cycle Length

Common injectable blocks run 6-12 weeks before comparing infection burden, immune context, and tolerability notes. [17][18][1]

What to expect

First weeks

Injectable Thymosin Alpha-1 immune-oriented use may show up as changes in fatigue, infection burden, inflammatory symptoms, or immune-lab patterns. [1][2][3][17][18]

Weeks 6-12

Injectable immune-response blocks may show changes in symptom frequency, viral or inflammatory context, and concurrent-therapy response. [1][2][3][17][18]

After stopping

Immune-marker or symptom patterns may drift after injectable Thymosin Alpha-1 ends if the underlying condition remains active. [1][2][3][17][18]

Safety profile

Thymosin Alpha-1 safety is injectable and immune-focused: injection reactions, fatigue, headache, immune disease context, concurrent therapy, and compounding quality matter. [17][1][2][3]

Common side effects

Injection-site reactions [17][1][2][3]
Fatigue [17][1][2][3]
Headache [17][1][2][3]

Cautions

Autoimmune / transplant [17][1][2][3]
Active infection care [17][1][2][3]
Product quality [17][1][2][3]

What we don't know

Optimal duration, repeated-cycle safety, interaction effects with immunotherapies, and U.S. compounded-product consistency remain uncertain. [17][1][2][3]

Who Thymosin Alpha-1 is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding unless supervised
Pregnancy or breastfeeding unless supervised warrants medical review or avoidance for Thymosin Alpha-1. [17][1][2][3]
Transplant immunosuppression without specialist review
Transplant immunosuppression without specialist review warrants medical review or avoidance for Thymosin Alpha-1. [17][1][2][3]
Autoimmune flare without clinician oversight
Autoimmune flare without clinician oversight warrants medical review or avoidance for Thymosin Alpha-1. [17][1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Immunosuppressants / transplant drugs
Tacrolimus, cyclosporine, mycophenolate, steroids, or transplant regimens can conflict with immune-stimulation goals; this is an immune-modulation caution. [17][1][2][3]
Checkpoint inhibitors / biologics
Checkpoint inhibitors, cytokines, or immune biologics can make inflammatory or autoimmune symptoms harder to attribute; this is an immune-modulation caution. [17][1][2][3]
Vaccines / immune supplements
Vaccines or strong immune-stimulant supplements can overlap with fever, fatigue, and immune-response tracking; this is an immune caution. [17][1][2][3]

Regulatory status

United States

In the U.S. as of 2026-06-21, Thymosin Alpha-1 is not FDA-approved for the reviewed injectable route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval. [24][18][19][22][23]

Route	FDA drug approval	503A compounding
Injectable	Not Approved Thymosin Alpha-1 is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [18][19][22][23]	Flagged FDA safety-risk materials flag thymosin alpha-1 for significant immunogenicity, peptide-impurity, API-characterization, and inadequate safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval. [24][18][19][22][23]

Injectable

FDA drug approval

Not Approved

Thymosin Alpha-1 is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [18][19][22][23]

503A compounding

Flagged

FDA safety-risk materials flag thymosin alpha-1 for significant immunogenicity, peptide-impurity, API-characterization, and inadequate safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval. [24][18][19][22][23]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [25][26][27][28]

Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Thymosin Alpha-1 injectable route as athlete-cleared without sport-specific review. [20][18][19][22][23]

How it works

Thymosin alpha-1 is discussed around T-cell maturation, dendritic-cell signaling, interferon pathways, innate immune coordination, and antiviral host response. In plain terms, it is an immune-response modulator rather than a direct antimicrobial drug. [1][2][3]

Injectable thymalfasin-style exposure makes the clinical context important. The same immune-modulating position can be useful or risky depending on infection status, cancer status, immune suppression, autoimmune history, and whether it is used as adjunctive therapy. Protocol meaning depends on a defined immune problem and route, not broad immune support. [1][2][3]

Research gaps & open questions

What the current literature has not yet settled about Thymosin Alpha-1:

A key evidence gap is modern trials against current antiviral and oncology standards. [1][2][3]

A key evidence gap is u.S. compounded-product quality and equivalence. [1][2][3]

A key evidence gap is long-term off-label immune-wellness safety. [1][2][3]

Common questions

Is thymosin alpha-1 FDA-approved in the United States?

No. Thymosin alpha-1 is not FDA-approved as a U.S. drug product, and FDA lists it with compounding safety concerns. [18][19][17][1][24][22]

Is thymosin alpha-1 approved internationally?

Yes, in some country-specific thymalfasin approvals. EU/Europe, UK, Canada, and Australia status still needs product-by-product regulatory checking. [18][19][17][1]

Is it just an immune booster?

No. It is better described as an immune-modulating mechanism; boosting is too vague and can be unsafe in autoimmune or transplant contexts. [18][19][17][1]

Myths & misconceptions

Myth

Everyone benefits from immune boosting.

Reality

Immune modulation can be harmful in autoimmune, transplant, cancer, or infection contexts. [1][2][3]

Myth

International use means U.S. approval.

Reality

Regulatory status is country-specific. [1][2][3]

History & discovery

Thymosin alpha-1 emerged when thymic-fraction research separated a defined 28-amino-acid immune peptide from crude thymus extracts. Its history is immunology first, not general wellness. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3]

Isolation and characterization of thymosin alpha-1 turned a broad thymus-extract story into a specific immune-modulating molecule. That made clinical development and product identity more interpretable. [1][2][3]

Historical reviews describe thymalfasin use in infectious-disease contexts outside the United States. That shaped international familiarity while leaving U.S. approval and compounded-product questions separate. [1][2][3]

Published research 20 studies

[1]

Thymosin alpha-1.

Am J Health Syst Pharm, 2001 May 15. review.

[2]

Historical review of thymosin α 1 in infectious diseases.

Expert Opin Biol Ther, 2015. review.

[3]

Thymosin alpha1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application.

Molecules, 2023 Apr 17. review.

[4]

Serum thymosin alpha 1 levels in normal and pathological conditions.

Expert Opin Biol Ther, 2018 Jul. review.

[5]

Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.

Antiviral Res, 2008 Feb. review.

[6]

From lab to bedside: emerging clinical applications of thymosin alpha 1.

Expert Opin Biol Ther, 2009 May. review.

[7]

Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.

J Gastroenterol Hepatol, 2004 Dec. review.

[8]

Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.

J Gastroenterol Hepatol, 2004 Dec. review.

[9]

Chronic hepatitis B: current and future treatment options.

Pharmacotherapy, 2002 Jun. review.

[10]

Thymalfasin: an immune system enhancer for the treatment of liver disease.

J Gastroenterol Hepatol, 2004 Dec. review.

[11]

Thymalfasin: an immune system enhancer for the treatment of liver disease.

J Gastroenterol Hepatol, 2004 Dec. review.

[12]

Medical management of chronic liver diseases in children (part I): focus on curable or potentially curable diseases.

Paediatr Drugs, 2011 Dec 1. review.

[13]

Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents.

Antiviral Res, 1994 Jul. review.

[14]

Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C.

Rev Med Virol, 2003 Nov-Dec. review.

[15]

[Characteristics of the hepatitis C virus and viral predictors of therapeutic response].

Med Klin (Munich), 1999 Nov 15. review.

[16]

Evolving therapies for the treatment of chronic hepatitis B virus infection.

Expert Opin Investig Drugs, 2002 Feb. review.

[17]

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

U.S. Food and Drug Administration. regulatory.

[18]

Drugs@FDA/openFDA query for Thymosin Alpha-1

U.S. Food and Drug Administration. database query.

[19]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[20]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.